It’s only fair to share… Navlimetostat CAS 2630904-45-7 ALSO 2630904-44-6 MF C23H18ClFN6O2 MW464.9 g/mol (2M)-2-{4-[4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl] -1-methyl-1H-pyrazol-5-yl}-4-chloro-6-(cyclopropyloxy)-3-fluorobenzonitrileantineoplastic, MRTX-1719, BMS-986504, MRTX 1719, BMS 986504 Navlimetostat (also known as MRTX-1719 or BMS-986504) is an investigational, first-in-class oral targeted cancer therapy being developed by Bristol-Myers Squibb. It works by selectively binding to the PRMT5-MTA complex, exploiting synthetic lethality to kill …